Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Receivables (2022 - 2025)

Amylyx Pharmaceuticals has reported Change in Receivables over the past 4 years, most recently at -$44000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at -$44000.0 for Q4 2025, up 96.57% from a year ago — trailing twelve months through Dec 2025 was -$359000.0 (up 99.09% YoY), and the annual figure for FY2025 was -$359000.0, up 99.09%.
  • Change in Receivables for Q4 2025 was -$44000.0 at Amylyx Pharmaceuticals, down from $30000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for AMLX hit a ceiling of $15.9 million in Q2 2023 and a floor of -$19.7 million in Q1 2024.
  • Median Change in Receivables over the past 4 years was -$147000.0 (2025), compared with a mean of -$3692.3.
  • Biggest five-year swings in Change in Receivables: plummeted 975.86% in 2024 and later soared 101.27% in 2025.
  • Amylyx Pharmaceuticals' Change in Receivables stood at $15.2 million in 2022, then fell by 29.48% to $10.7 million in 2023, then plummeted by 111.99% to -$1.3 million in 2024, then soared by 96.57% to -$44000.0 in 2025.
  • The last three reported values for Change in Receivables were -$44000.0 (Q4 2025), $30000.0 (Q3 2025), and -$198000.0 (Q2 2025) per Business Quant data.